A novel nanocomposite drug delivery system for SARS-CoV-2 infections
Uday Chintapula, Shazeed-Ul Karim, Priyanka Iyer, Haritha Asokan‐Sheeja, Biswas Neupane, Farzana Nazneen, He Dong, Fengwei Bai, Kytai T. Nguyen
Abstract
and 48 h. RDV NCs were spherically shaped with a size range of 200-300 nm and a zeta potential of ∼+31 mV as well as indicating the presence of coated nanofibers. Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR), immunofluorescence and plaque assays of SARS-CoV-2 infected Vero E6 treated with RDV NCs showed significantly higher antiviral activities compared to those of free drug and uncoated RDV NPs. RDV NCs exhibited high antiviral activity against SARS-CoV-2, and the nanocomposite platform has the potential to be developed into an inhalable drug delivery system for other viral infections in the lungs.